Callan Family Office LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN

Posted by Stanley Muller on Aug 22nd, 2026

Callan Family Office LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 10,138 shares of the biopharmaceutical company’s stock, valued at approximately $6,321,000.

Several other large investors also recently made changes to their positions in REGN. WPG Advisers LLC increased its holdings in Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 25 shares during the last quarter. Western Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the first quarter valued at $26,000. SHP Wealth Management acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $26,000. Titan Wealth CI Ltd bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $29,000. Finally, Kemnay Advisory Services Inc. bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $31,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $834.04 on Friday. The firm has a market capitalization of $85.87 billion, a PE ratio of 20.61, a PEG ratio of 1.41 and a beta of 0.22. The company’s 50-day moving average is $697.09 and its 200-day moving average is $716.73. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $847.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. Regeneron Pharmaceuticals’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter last year, the company posted $12.81 EPS. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be issued a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Positive Sentiment: The FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Approval was supported by the Phase 3 OPTIMA trial, which showed a 90% or greater reduction in new lesions at 56 weeks. As the first approved treatment demonstrating this benefit in FOP, Pasatru could expand Regeneron’s rare-disease portfolio and create a new revenue stream. Regeneron to challenge Ipsen as FDA clears bone disease drug
Positive Sentiment: Regeneron is also pursuing growth in obesity treatment. An update on its Phase 2 olatorepatide study has drawn investor attention because the program could give the company exposure to the large and rapidly expanding obesity-drug market, although clinical and commercial risks remain. Regeneron’s Olatorepatide Trial Signals a Bid for Obesity Market Upside
Neutral Sentiment: Multiple investor-law-firm notices announced a securities class action and a September 14, 2026 lead-plaintiff deadline. The claims relate to alleged disclosures about the Phase 3 Fianlimab-Libtayo melanoma trial; the notices themselves do not represent a new regulatory or operating development. Regeneron Investors Class Action Notice
Negative Sentiment: The underlying litigation alleges that Regeneron misled investors about the viability and prospects of the Fianlimab-Libtayo trial, whose disappointing results reportedly caused a sharp share-price decline and an approximately $11 billion reduction in market value. Continued lawsuit announcements add reputational, legal-cost and potential financial-liability risks. Pomerantz Regeneron Investor Alert

Insiders Place Their Bets

In other news, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $320,000.00. Following the transaction, the director owned 603 shares of the company’s stock, valued at approximately $482,400. This represents a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,400 shares of company stock worth $1,090,030 over the last three months. Insiders own 6.97% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on REGN. Royal Bank Of Canada upped their target price on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a “sector perform” rating in a report on Friday, July 31st. Morgan Stanley lifted their price target on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. HSBC lowered their price target on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a research report on Tuesday, July 7th. Finally, Sanford C. Bernstein raised Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. Sixteen equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $801.70.

Check Out Our Latest Analysis on REGN

Regeneron Pharmaceuticals Profile

(Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.